Drug intelligence / Profile preview

Cutisanol Pó

Development stage: Unknown
Lead developer: MR Pharma
Modality: Small Molecules
Administration: Topical

Overview

Cutisanol Pó is a topical dermatological powder developed by the Brazilian pharmaceutical company Millet Roux (MR Pharma). It is a combination product containing bismuth subgallate, zinc oxide, and thymol iodide. The formulation acts as an antiseptic and drying agent, creating a protective barrier on the skin to reduce irritation and promote healing. It is primarily indicated for the prevention and treatment of diaper dermatitis, diaper rash, heat rash (prickly heat), eczema, and various other skin irritations. Marketed since 1941, it is approved for both adult and pediatric use and is typically applied to clean, dry skin multiple times daily.

Brand names: Cutisanol PóCutisanol Powder
Other names: Cutisanol

Beyond the preview

Go deeper on Cutisanol Pó.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cutisanol Pó.

Explore the full profile